Status:
UNKNOWN
Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in Heart Failure Patients With Impaired Ejection Fraction
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Levosimendan
Cardiac Surgery
Eligibility:
All Genders
18+ years
Brief Summary
Levosimendan, a drug with inotropic, vasodilatory and myocardial protective properties, has been proposed for the prevention and treatment of postoperative low cardiac output syndrome in cardiac surge...
Eligibility Criteria
Inclusion
- Patients with heart failure impaired LVEF (\< 40%), who have undergone left heart surgery (coronary artery bypass grafting and/or mitral and/or aortic valve replacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 at different University Hospital in France
Exclusion
- Initiation of levosimendan \> 48 hours or \< 24 hours before surgery ECMO pre- or post-op
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 10 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06021587
Start Date
July 1 2023
End Date
October 10 2023
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
'CHRU Nancy
Vandœuvre-lès-Nancy, Meurthe Et Moselle, France, 54530